image credit- shutterstock
Alkem Laboratories has announced the launch of Empanorm in India, a generic version of empagliflozin, for the treatment of type-2 diabetes mellitus, chronic kidney disease (CKD), and chronic heart failure (HF). The product is priced approximately 80% lower than the innovator drugs, making it more accessible to patients.
Alkem’s Empanorm is bioequivalent to the innovator products and features an anti-counterfeit security band on the packaging. It also includes patient education materials in Hindi and English, along with QR codes providing additional information on diabetes, heart failure, and CKD in 11 languages. To enhance patient convenience, Alkem has introduced the medicine in a smaller tablet size.
The generic empagliflozin is available under the brand name “Empanorm” and its combinations namely: (i) empagliflozin and linagliptin is available under the name “Empanorm L”; (ii) empagliflozin and sitagliptin is available under the name “Empanorm Duo” and “Alsita E”; and (iii) empagliflozin and metformin is available under the name “Empanorm M”.
Dr Vikas Gupta, Chief Executive Officer, Alkem, said, “As we expand and strengthen our chronic portfolio, the introduction of generic empagliflozin in India is an important milestone. This globally-accepted molecule has transformed diabetes care with its additional benefits in managing chronic kidney disease and cardiovascular health. Leveraging Alkem’s strong distribution network, we aim to make this therapy widely available, enhancing treatment accessibility and improving health outcomes for patients across the country.”
